Moderna, Inc. (MRNA)

Market Cap	10.60B
Revenue (ttm)	3.08B
Net Income (ttm)	-2.90B
Shares Out	390.58M
EPS (ttm)	-7.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,876,658
Open	27.85
Previous Close	27.72
Day's Range	27.11 - 28.48
52-Week Range	23.15 - 58.45
Beta	2.01
Analysts	Hold
Price Target	41.50 (+52.91%)
Earnings Date	Nov 6, 2025

About MRNA

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 7, 2018
• Employees: 5,800
• Stock Exchange: NASDAQ
• Ticker Symbol: MRNA
• Website: https://www.modernatx.com

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Analyst Summary

According to 16 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $41.5, which is an increase of 52.91% from the latest price.

Price Target

$41.5

(52.91% upside)

Analyst Consensus: Hold